| [1] CHI A C, DAY T A, NEVILLE B W. Oral cavity and oropharyngeal squamous cell carcinoma--an update [J]. CA Cancer J Clin, 2015, 65(5): 401-21.[2] SCULLY C, BAGAN J. Oral squamous cell carcinoma overview [J]. Oral Oncol, 2009, 45(4-5): 301-8.[3] BELLO I O, SOINI Y, SALO T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II) [J]. Oral Oncol, 2010, 46(9): 636-43.[4] SUVA M L, RIGGI N, BERNSTEIN B E. Epigenetic reprogramming in cancer [J]. Science, 2013, 339(6127): 1567-70.[5] SIMON J A, KINGSTON R E. Mechanisms of polycomb gene silencing: knowns and unknowns [J]. Nat Rev Mol Cell Biol, 2009, 10(10): 697-708.[6] MARGUERON R, REINBERG D. The Polycomb complex PRC2 and its mark in life [J]. Nature, 2011, 469(7330): 343-9.[7] LI Z, WANG Y, QIU J, et al. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer [J]. Oncotarget, 2013, 4(12): 2532-49.[8] LI Z, WANG Y, YUAN C, et al. Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer [J]. Lab Invest, 2014, 94(12): 1431-45.[9] HE Q, LIU Z, ZHAO T, et al. Bmi1 drives stem-like properties and is associated with migration, invasion, and poor prognosis in tongue squamous cell carcinoma [J]. Int J Biol Sci, 2015, 11(1): 1-10.[10] CAO R, ZHANG Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex [J]. Mol Cell, 2004, 15(1): 57-67.[11] LI H, CAI Q, WU H, et al. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK [J]. Mol Cancer Res, 2012, 10(11): 1462-72.[12] LIU C, SHI X, WANG L, et al. SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis [J]. Tumour Biol, 2014, 35(6): 6073-82.[13] LIU Y L, GAO X, JIANG Y, et al. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer [J]. J Cancer Res Clin Oncol, 2015, 141(4): 661-9.[14] PASINI D, DI CROCE L. Emerging roles for Polycomb proteins in cancer [J]. Curr Opin Genet Dev, 2016, 36(50-8.[15] SAUVAGEAU M, SAUVAGEAU G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer [J]. Cell Stem Cell, 2010, 7(3): 299-313.[16] LEE S R, ROH Y G, KIM S K, et al. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer [J]. Clin Cancer Res, 2015, 21(23): 5391-403.[17] GONZALEZ-RAMIREZ I, SOTO-REYES E, SANCHEZ-PEREZ Y, et al. Histones and long non-coding RNAs: the new insights of epigenetic deregulation involved in oral cancer [J]. Oral Oncol, 2014, 50(8): 691-5.[18] JITHESH P V, RISK J M, SCHACHE A G, et al. The epigenetic landscape of oral squamous cell carcinoma [J]. Br J Cancer, 2013, 108(2): 370-9.[19] HERRANZ N, PASINI D, DIAZ V M, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor [J]. Mol Cell Biol, 2008, 28(15): 4772-81.[20] XIA R, JIN F Y, LU K, et al. SUZ12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and E-cadherin [J]. Tumour Biol, 2015, 36(7): 5341-51.[21] ILIOPOULOS D, LINDAHL-ALLEN M, POLYTARCHOU C, et al. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells [J]. Mol Cell, 2010, 39(5): 761-72.[22] CREA F, HURT E M, MATHEWS L A, et al. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer [J]. Mol Cancer, 2011, 10(40. |
